Johnson & Johnson’s Office of the Chief Medical Officer (OCMO) works to ensure that the safety data underpinning all our product are scientifically sound and robust; following from that, it is also an OCMO priority to provide healthcare practitioners, physicians, surgeons, patients and consumers with the most informative data and understanding of the safety of our products so that they may make well informed healthcare decisions.
To that end, Johnson & Johnson Innovation and the OCMO are looking to reward up to $200,000 in multiple grants, and one year of JLABS space, to the individuals or teams who submit the best ideas on how to educate, inform and provide clarity around healthcare product safety.
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential to impact healthcare outcomes / move the needle on medical safety
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- Clarity of plan: Milestones & defined go/no go decisions
Deadline to apply is May 24, 2017
Winner(s) will be announced in November
Why this challenge matters to us
True benefit from healthcare products requires an unrelenting focus on patient- and consumer-centered safety, a principle that is at the heart of Johnson & Johnson’s Credo and is embodied in the mission of the Office of the Chief Medical Officer (OCMO). Working to ensure that J&J is developing and making available the safest products possible is what the nearly 1000 employees of OCMO work towards each day. Always looking for better ways to address safety on behalf of patients and consumers, we are embarking on a Quickfire Challenge to identify new and innovative ideas to increase the safe use of our products.
The QuickFire Challenge innovation focus areas are:
• Empowering patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products).
This challenge focus area seeks ways to maximize consumer and patient education and understanding of healthcare products and their safety and efficacy, including medical devices, pharmaceuticals and consumer products. The objective is to empower patients, consumers and healthcare providers to make more informed decisions and obtain maximum benefit from product use through greater understanding of safety data and by ensuring more effective communication and enhancing education.
• Improving training and development for surgeons by identifying new models that simulate the operating room environment.
This focus area seeks new and robust models and methods to evaluate medical devices used by surgeons in a simulated environment representative of operating room procedures, with the goal of helping the surgeon understand how to safely and effectively use a medical device and understand variability in device and performance/outcome. Entries should focus on soft tissue models that anatomically represent organ-specific anatomic features and biological properties, such as tissue injury, bleeding and clotting responses.
• Empowering patients and consumers to more safely administer and handle healthcare products.
The third focus area seeks ways to address the challenge of prescription medication errors. Entries should identify patient- and consumer-focused devices, solutions or platforms that will prevent errors and solutions to promote safe storage and administration or extend the shelf life of prescription, over-the-counter or cosmetic products.
“Entrants can submit ideas in one of three focus areas that are critical for ensuring that we make the safest possible products on behalf of patients and consumers,” said Melinda Richter, Head of Johnson & Johnson Innovation, JLABS. “In addition to funding, Advancing the Safe Use of Healthcare Products QuickFire Challenge winners will be awarded JLABS support that includes infrastructure, services, educational programs and networks in global hotspots.”